Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

273
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
273
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

841
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
841
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

468
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
468

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Calcium influx through T-type calcium channels regulates secondary necrosis and inflammation through recruitment of ATG9A-mediated membrane repair.

Cell death & disease·2026
Same author

Compacted solid implant formulations for long-term buprenorphine delivery.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Bimodal Plasmonic Devices Reveal Extensive Collagen Deposition in Mesenchymal Stem Cells Cultured on 3D Self-Assembled Peptide Scaffolds via a Birefringence-Induced Colorimetric Response.

Macromolecular bioscience·2025
Same author

CD14 Blockade Modulates Macrophage-Mediated Immunological Injury in a Translational Model of Reperfused ST-Segment Elevation Myocardial Infarction.

JACC. Basic to translational science·2025
Same author

Morphological Evidence for a Directional Flow Mechanoreceptor in Olive-Headed Sea Snakes (Hydrophis major).

Journal of morphology·2025
Same author

Challenges and innovations in long-acting injectable formulations: can formulation design space be rationalized?

The Journal of pharmacy and pharmacology·2025

相关实验视频

Updated: Sep 13, 2025

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

37.5K

长效注射性布普伦诺芬PLGA微粒配方的长效注射性布普伦诺芬

Andrew Otte1, Chad Johnson2, John Garner2

  • 1Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA.

International journal of pharmaceutics
|July 29, 2025
PubMed
概括

研究人员开发了一种长期作用的注射性布普伦诺芬微粒配方,用于治疗阿片类药物使用障碍 (OUD). 这种新配方提供了持续释放超过三个月,为OUD管理提供了一个有前途的治疗选择.

关键词:
这是一种布普伦诺芬.长效的注射剂 长效的注射剂片类药物使用障碍.在PLGA微粒中.在 S/O/W 乳液中.

更多相关视频

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

65.6K
Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

14.6K

相关实验视频

Last Updated: Sep 13, 2025

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

37.5K
PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

65.6K
Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

14.6K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 材料科学 材料科学 材料科学
  • 药物输送系统 药物输送系统

背景情况:

  • 阿片类药物使用障碍 (OUD) 构成了全球重大健康挑战,导致高发病率和死亡率.
  • 对OUD的药物,如布普伦诺芬,在减少非法阿片类药物使用,过量死亡和医疗保健费用方面是有效的.
  • 布普伦诺啡因的特性使其适合开发长效配方,以改善治疗坚持和结果.

研究的目的:

  • 开发一种新的3个月长效注射性布普伦诺芬微粒配方,用于治疗OUD.
  • 为了达到35-40%的目标药物负载和至少3个月的体内药物释放.

主要方法:

  • 使用固体-在-油-在-水 (S/O/W) 乳液技术进行微粒制造.
  • 在油阶段使用的具有特定材料属性的 (85:15,MW=108kDa) 聚乳糖酸 (PLGA) 含量为15.2% w/v.
  • 优化了关键处理参数,包括以乙酸乙烯作为溶剂和用25%乙醇溶液进行8小时的后处理.

主要成果:

  • 在大鼠模型中进行的一项药理动力学研究表明,布普伦诺芬持续释放.
  • 药物度在60多天内保持在2 ng/mL以上,并在另外40天内保持在1 ng/mL以上.
  • 该配方在很长一段时间内保持了治疗性布普伦诺芬水平 (≥1 ng/mL),与现有的商业选择相美.

结论:

  • 通过S/O/W乳液方法成功开发了一种可行的长效注射布普伦诺芬微粒配方.
  • 该配方显示持续释放药物≥3个月,符合目标产品配置文件.
  • 这种长效配方具有改善OUD治疗管理和患者坚持治疗的潜力.